Regular Article THROMBOSIS AND HEMOSTASIS Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits
نویسندگان
چکیده
• Antisense oligonucleotides reduce levels of target hepatic mRNA and protein and decrease clotting activity in rabbits. • Selective depletion of factors XI and XII in rabbits attenuates catheter thrombosis, whereas factor VII depletion does not. Central venous catheter thrombosis can cause venous obstruction and pulmonary embolism. To determine the extent to which catheter thrombosis is triggered by the contact or extrinsic pathway of coagulation, we used antisense oligonucleotides (ASOs) to selectively knock down factor (f)XII, fXI, or high-molecular-weight kininogen (HK), key components of the contact pathway, or fVII, which is essential for the extrinsic pathway. Knockdown of contact pathway components prolonged the activated partial thromboplastin time and decreased target protein activity levels by over 90%, whereas fVII knockdown prolonged the prothrombin time and reduced fVII activity to a similar extent. Using a rabbit model of catheter thrombosis, catheters implanted in the jugular veinwere assessed daily until they occluded, up to a maximum of 35 days. Compared with control, fXII and fXI ASO treatment prolonged the time to catheter occlusion by 2.2and 2.3-fold, respectively. In contrast, both HK and fVII knockdown did not significantly prolong the time to occlusion, and dual treatment with fVIIand fXI-directed ASOs produced a time to occlusion similar to that with the fXI ASO alone. These findings suggest that catheter thrombosis is triggered via the contact pathway and identify fXII and fXI as potential targets to attenuate this complication. (Blood. 2014;123(13):2102-2107)
منابع مشابه
Making (anti)sense of factor XI in thrombosis.
Inhibiting thrombosis without inducing bleeding is the holy grail of anticoagulant therapy. Currently, there are no commercially available anticoagulants that achieve this goal. Although many antithrombotic agents improve survival by interfering with vessel thrombosis, this protection always comes at the cost of an increased risk of bleeding. The observation that inhibitors of thrombosis increa...
متن کاملThrombosis Prevention without Anticoagulation
The ultimate goal for hematologists, cardiologists, and vascular medicine physicians is to find agents that prevent thrombosis without creating defects in hemostasis (the cessation of bleeding). To a great extent, this notion was considered an impossible dream. However, recent advances in understanding of the plasma contact activation, kallikrein/kinin, renin angiotensin, and other vasoregulato...
متن کاملAntithrombotic effect of antisense factor XI oligonucleotide treatment in primates.
OBJECTIVE During coagulation, factor IX (FIX) is activated by 2 distinct mechanisms mediated by the active proteases of either FVIIa or FXIa. Both coagulation factors may contribute to thrombosis; FXI, however, plays only a limited role in the arrest of bleeding. Therefore, therapeutic targeting of FXI may produce an antithrombotic effect with relatively low hemostatic risk. APPROACH AND RESU...
متن کاملSelective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding.
Recent studies indicate that the plasma contact system plays an important role in thrombosis, despite being dispensable for hemostasis. For example, mice deficient in coagulation factor XII (fXII) are protected from arterial thrombosis and cerebral ischemia-reperfusion injury. We demonstrate that selective reduction of prekallikrein (PKK), another member of the contact system, using antisense o...
متن کاملTHROMBOSIS AND HEMOSTASIS Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk
Existing anticoagulants effectively inhibit the activity of coagulation factors of the extrinsic and common pathway but have substantial limitations and can cause severe bleeding complications. Here we describe a novel therapeutic approach to thrombosis treatment. We have developed and characterized the efficacy and safety of selective second-generation antisense oligonucleotides (ASOs) targeti...
متن کامل